## **David Briggs**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5648495/publications.pdf Version: 2024-02-01



DAVID RDICCS

#	Article	IF	CITATIONS
1	BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation. International Journal of Immunogenetics, 2022, 49, 22-29.	1.8	5
2	Dynamic Behaviour of Donor Specific Antibodies in the Early Period Following HLA Incompatible Kidney Transplantation. Transplant International, 2022, 35, 10128.	1.6	4
3	Immunoglobulin isotype compositions of ABO specific antibodies are dependent on the individual patient blood group and blood group specificity: Results from a healthy donor cohort. Journal of Immunological Methods, 2021, 494, 113053.	1.4	1
4	HLA Antibody Incompatible Renal Transplantation: Long-term Outcomes Similar to Deceased Donor Transplantation. Transplantation Direct, 2021, 7, e732.	1.6	7
5	Rapid, highly accurate and costâ€effective openâ€source simultaneous complete <scp>HLA</scp> typing and phasing of class I and <scp>II</scp> alleles using nanopore sequencing. Hla, 2020, 96, 163-178.	0.6	20
6	C3dâ€positive donorâ€specific antibodies have a role in pretransplant risk stratification of crossâ€matchâ€positive HLAâ€incompatible renal transplantation: United Kingdom multicentre study. Transplant International, 2020, 33, 1128-1139.	1.6	5
7	Update to the study protocol, including statistical analysis plan, for the multicentre, randomised controlled OuTSMART trial: a combined screening/treatment programme to prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies. Trials, 2019, 20, 476.	1.6	4
8	Decision tree and random forest models for outcome prediction in antibody incompatible kidney transplantation. Biomedical Signal Processing and Control, 2019, 52, 456-462.	5.7	211
9	Direct quantitative measurement of the kinetics of HLA-specific antibody interactions with isolated HLA proteins. Human Immunology, 2018, 79, 122-128.	2.4	16
10	A new data-driven model for post-transplant antibody dynamics in high risk kidney transplantation. Mathematical Biosciences, 2017, 284, 3-11.	1.9	9
11	A disease-linked <i>ULBP6</i> polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. Science Signaling, 2017, 10, .	3.6	23
12	The UK National Registry of ABO and HLA Antibody Incompatible Renal Transplantation: Pretransplant Factors Associated With Outcome in 879 Transplants. Transplantation Direct, 2017, 3, e181.	1.6	26
13	Clinical outcomes with ABO antibody titer variability in a multicenter study of ABOâ€incompatible kidney transplantation in the United Kingdom. Transfusion, 2016, 56, 2668-2679.	1.6	20
14	Subclass analysis of donor <scp>HLA</scp> â€specific IgG in antibodyâ€incompatible renal transplantation reveals a significant association of IgG <sub>4</sub> with rejection and graft failure. Transplant International, 2015, 28, 1405-1415.	1.6	53
15	Novel data-driven stochastic model for antibody dynamics in kidney transplantationâ^—â^—This work has been supported by EPSRC UK (EP/K02504X/1) IFAC-PapersOnLine, 2015, 48, 249-254.	0.9	Ο
16	Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation. Human Immunology, 2015, 76, 546-552.	2.4	35
17	ABO-Incompatible Renal Transplantation Without Antibody Removal Using Conventional Immunosuppression Alone. American Journal of Transplantation, 2015, 15, 1728-1729.	4.7	7
18	Transitional B Lymphocytes Are Associated With Protection From Kidney Allograft Rejection: A Prospective Study. American Journal of Transplantation, 2015, 15, 1384-1391.	4.7	96

#	Article	IF	CITATIONS
19	The use of NGAL and IP-10 in the prediction of early acute rejection in highly sensitized patients following HLA-incompatible renal transplantation. Transplant International, 2014, 27, 362-370.	1.6	22
20	Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial. Trials, 2014, 15, 30.	1.6	8
21	Profiling antibodies to class II HLA in transplant patient sera. Human Immunology, 2014, 75, 261-270.	2.4	10
22	HLA incompatible combined liver–kidney transplantation: Dynamics of antibody modulation revealed by a novel approach to HLA antibody characterisation. Transplant Immunology, 2014, 30, 30-33.	1.2	8
23	No Progress in ABO Titer Measurement. Transplantation, 2014, 97, e19-e21.	1.0	16
24	Influence of preformed donor-specific antibodies and C4d on early liver allograft function. Scandinavian Journal of Gastroenterology, 2013, 48, 1444-1451.	1.5	4
25	Structural identifiability of surface binding reactions involving heterogeneous analyte: Application to surface plasmon resonance experiments. Automatica, 2013, 49, 48-57.	5.0	22
26	Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Human Immunology, 2013, 74, 666-672.	2.4	55
27	Skewing of Female X-Chromosome Inactivation. Transplantation, 2013, 95, e25-e28.	1.0	7
28	Behaviour of Non-Donor Specific Antibodies during Rapid Re-Synthesis of Donor Specific HLA Antibodies after Antibody Incompatible Renal Transplantation. PLoS ONE, 2013, 8, e68663.	2.5	4
29	Human leukocyte antigen antibody incompatible renal transplantation. Indian Journal of Nephrology, 2012, 22, 409.	0.5	7
30	Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure. Journal of the American Society of Nephrology: JASN, 2012, 23, 1891-1899.	6.1	65
31	Estimation of antibody binding affinities in incompatible blood type renal transplants from surface plasmon resonance. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 97-102.	0.4	0
32	Human Leukocyte Antigen-Specific Antibodies and Gamma-Interferon Stimulate Human Microvascular and Glomerular Endothelial Cells to Produce Complement Factor C4. Transplantation, 2012, 93, 867-873.	1.0	16
33	The genotype of <i><scp>RAET1L</scp></i> ( <i><scp>ULBP6</scp></i> ), a ligand for human <scp>NKG2D</scp> ( <scp>KLRK1</scp> ), markedly influences the clinical outcome of allogeneic stem cell transplantation. British Journal of Haematology, 2012, 159, 589-598.	2.5	20
34	Cryofiltration in the Treatment of Cryoglobulinemia and HLA Antibodyâ€Incompatible Transplantation. Therapeutic Apheresis and Dialysis, 2012, 16, 91-96.	0.9	10
35	Human Leukocyte Antigen Antibody-Incompatible Renal Transplantation: Excellent Medium-Term Outcomes With Negative Cytotoxic Crossmatch. Transplantation, 2011, 92, 900-906.	1.0	66
36	T Lymphocyte Responses to Nonpolymorphic HLA-Derived Peptides Are Associated With Chronic Renal Allograft Dysfunction. Transplantation, 2011, 91, 279-286.	1.0	12

#	Article	IF	CITATIONS
37	Antibody-Associated Rejection in Liver Transplantation: Keep on Knocking, and the Door Will Be Opened to You. American Journal of Transplantation, 2011, 11, 1767-1768.	4.7	1
38	KIR and HLA-C Interactions Promote Differential Dendritic Cell Maturation and Is a Major Determinant of Graft Failure following Kidney Transplantation. PLoS ONE, 2011, 6, e23631.	2.5	20
39	Chronic Graft Versus Host Disease Is Associated With an Immune Response to Autologous Human Leukocyte Antigen–Derived Peptides. Transplantation, 2010, 90, 555-563.	1.0	3
40	Association of Caveolin-1 Gene Polymorphism With Kidney Transplant Fibrosis and Allograft Failure. JAMA - Journal of the American Medical Association, 2010, 303, 1282.	7.4	65
41	British Society for Histocompatibility & Immunogenetics and British Transplantation Society Guidelines for the Detection and Characterisation of Clinically Relevant Antibodies in Allotransplantation. International Journal of Immunogenetics, 2010, 37, 435-437.	1.8	29
42	Double Filtration Plasmapheresis in Antibodyâ€Incompatible Kidney Transplantation. Therapeutic Apheresis and Dialysis, 2010, 14, 392-399.	0.9	44
43	Estimation of kinetic rate constants from surface plasmon resonance experiments. , 2010, , .		0
44	The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantation. Nephrology Dialysis Transplantation, 2010, 25, 1306-1312.	0.7	11
45	Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation. Transplant Immunology, 2010, 23, 161-165.	1.2	19
46	Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations. Human Immunology, 2010, 71, 610-620.	2.4	29
47	Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome. Rheumatology, 2009, 48, 359-362.	1.9	22
48	Ethnic variability in human leukocyte antigenâ€E haplotypes. Tissue Antigens, 2009, 73, 39-45.	1.0	36
49	Rises and Falls in Donor-Specific and Third-Party HLA Antibody Levels After Antibody Incompatible Transplantation. Transplantation, 2009, 87, 882-888.	1.0	36
50	Donor HLA-C Genotype Has a Profound Impact on the Clinical Outcome Following Liver Transplantation. American Journal of Transplantation, 2008, 8, 1931-1941.	4.7	66
51	NEW CHOICES FOR PATIENTS NEEDING KIDNEY TRANSPLANTATION ACROSS ANTIBODY BARRIERS. Journal of Renal Care, 2008, 34, 85-93.	1.2	6
52	Development of Non-Donor-Specific HLA Antibodies after Kidney Transplantation: Frequency and Clinical Implications. Contributions To Nephrology, 2008, 162, 107-116.	1.1	13
53	Variation in Iron Homeostasis Genes Between Patients With ARDS and Healthy Control Subjects. Chest, 2008, 133, 1302-1311.	0.8	35
54	Application of Flow Cytometry to Monitor Antibody Levels in ABO Incompatible Kidney Transplantation. Transplantation, 2008, 86, 474-477.	1.0	31

#	Article	IF	CITATIONS
55	Blood Levels of Donor-Specific Human Leukocyte Antigen Antibodies After Renal Transplantation: Resolution of Rejection in the Presence of Circulating Donor-Specific Antibody. Transplantation, 2007, 84, 876-884.	1.0	67
56	Indirect Recognition of T-Cell Epitopes Derived from the ?3 and Transmembrane Domain of HLA-A2. American Journal of Transplantation, 2007, 7, 1148-1157.	4.7	19
57	ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment Xenotransplantation, 2006, 13, 148-153.	2.8	50
58	A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis. International Journal of Immunogenetics, 2006, 33, 155-161.	1.8	18
59	Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood, 2005, 107, 1230-1232.	1.4	155
60	Donor KIR Genotype Does Not Affect VZV Reactivation after Allogeneic Haematopoietic Stem Cell Transplantation Blood, 2005, 106, 3236-3236.	1.4	0
61	The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood, 2004, 103, 1521-1526.	1.4	173
62	The distribution of 13 killer-cell immunoglobulin-like receptor loci in UK blood donors from three ethnic groups. International Journal of Immunogenetics, 2003, 30, 213-221.	1.2	49
63	Used leucodepletion filters as a source of large quantities of DNA suitable for the study of genetic variations in human populations. Transfusion Medicine, 2003, 13, 77-82.	1.1	7
64	Identification of a new HLA-DRB5 allele, DRB5*0112, by routine PCR-SSP. Tissue Antigens, 2003, 62, 554-555.	1.0	3
65	A Multi-Laboratory characterization of the KIR genotypes of 10th International Histocompatibility Workshop cell lines. Human Immunology, 2003, 64, 567-571.	2.4	24
66	Use of patient age and anti-Ro/La antibody status to determine the probability of patients with systemic lupus erythematosus and sicca symptoms fulfilling criteria for secondary Sjogren's syndrome. British Journal of Rheumatology, 2003, 42, 189-191.	2.3	9
67	The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology, 2002, 123, 444-449.	1.3	35
68	Importance of methodology in the flow cytometric crossmatch: A multicentre study. Transplantation Proceedings, 1997, 29, 1454-1455.	0.6	10
69	Impact of a large nonindigenous population on the renal transplant waiting list. Transplantation Proceedings, 1997, 29, 3724-3725.	0.6	7
70	A POSITIVE CROSSMATCH IN LIVER TRANSPLANTATION-NO EFFECT OR INAPPROPRIATE ANALYSIS?. Transplantation, 1997, 64, 54-59.	1.0	45
71	FcgammaRlla polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clinical and Experimental Immunology, 1996, 104, 264-268.	2.6	119
72	Class II MHC typing in pemphigoid gestationis. Clinical and Experimental Dermatology, 1995, 20, 123-126.	1.3	46

#	Article	IF	CITATIONS
73	A molecular and serologic analysis of the major histocompatibility complex and complement component c4 in systemic sclerosis. Arthritis and Rheumatism, 1993, 36, 943-954.	6.7	42
74	Anti-HLA antibodies in pemphigoid gestationis (herpes gestationis). British Journal of Dermatology, 1993, 129, 257-259.	1.5	35
75	The HLAâ€DP locus in systemic sclerosis – No primary association. Tissue Antigens, 1993, 42, 144-145.	1.0	6
76	Complement polymorphism in herpes gestationis: Association with C4 null allele. Journal of the American Academy of Dermatology, 1993, 29, 545-549.	1.2	53
77	The immunogenetic background of scleroderma-an overview. Clinical and Experimental Dermatology, 1992, 17, 73-78.	1.3	19
78	Analysis of complement C4 loci in Caucasoids and Japanese with idiopathic membranous nephropathy. Kidney International, 1992, 42, 882-887.	5.2	11
79	Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet, The, 1991, 338, 661-662.	13.7	127
80	Major histocompatibility complex class II genes and systemic sclerosis Annals of the Rheumatic Diseases, 1991, 50, 862-865.	0.9	13
81	Genetic and environmental factors in scleroderma. Current Opinion in Rheumatology, 1990, 2, 920-921.	4.3	6
82	Genetic Factors in Scleroderma. Rheumatic Disease Clinics of North America, 1990, 16, 31-51.	1.9	25
83	Genetic factors in scleroderma. Rheumatic Disease Clinics of North America, 1990, 16, 31-51.	1.9	7
84	Genetic and environmental factors in scleroderma. Current Opinion in Rheumatology, 1989, 1, 475-478.	4.3	2
85	HLA antigens in the Guillain-Barré syndrome. Journal of Neuroimmunology, 1988, 18, 13-16.	2.3	42
86	A strong association between null alleles at the C4A locus in the major histocompatibility complex and systemic sclerosis. Arthritis and Rheumatism, 1986, 29, 1274-1277.	6.7	40